---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-385362"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-09-08T21:16:50+00:00"
generated_at: "2026-09-08T21:18:09.802775+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Perspective Therapeutics updates 212Pb pipeline presentation; highlights NET/melanoma/FAP data targeting $45B market

## Summary
- Perspective Therapeutics updates corporate presentation for 212Pb radiopharma pipeline targeting a combined $45B+ solid tumor market.
- VMT-α-NET (SSTR2+ NETs): Phase 1/2a ASCO 2026 data shows durable disease control across all doses; safety profile from n=68 treated patients.
- VMT01 (melanoma/MC1R): preliminary anti-tumor activity at 3.0 mCi in Phase 1/2a; synergy with immune checkpoint inhibitors highlighted.
- PSV359 (FAP-ɑ) shows improved tumor retention in Phase 1/2a solid tumors; CCK2R81 in medullary thyroid cancer; data expected across programs in 2026.
- Platform supports direct-to-hospital delivery with regional 212Pb manufacturing and IP portfolio covering radiopharmaceutical value chain.

## SEC filing metadata
- accession: 0001193125-26-385362
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-09-08T21:16:50+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526385362/0001193125-26-385362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526385362/catx-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-385362
- JSON: https://secwatch.observer/filing/0001193125-26-385362.json
- Plain text: https://secwatch.observer/filing/0001193125-26-385362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.